1. FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis. (12th June 2018) Authors: Aranow, C.; Dall'Era, M.; Byron, M.; Ding, L.; Smilek, D.; Diamond, B.; Wofsy, D. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 690 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗